Compounding Pharmacy/Adulterated Drug Products: FDA Warning Letter to Pine Pharmaceuticals, LLC, 2026-08-07
Letter issued · posted to fda.gov .
Subject as published: Compounding Pharmacy/Adulterated Drug Products
TL;DR
Here's the summary: The FDA's Center for Drug Evaluation and Research issued Warning Letter WL #728537 on August 7, 2026, to Pine Pharmaceuticals, LLC (355 Riverwalk Parkway, Tonawanda, NY), an outsourcing facility registered under section 503B of the FDCA, citing serious deficiencies discovered during an FDA inspection from November 4-14, 2025. The violations include failure to disinfect materials transferring between cleanroom areas, inadequate environmental monitoring of high-touch staging trays, insufficient batch discrepancy investigations, lack of validated aseptic/sterilization procedures, insufficient staff training documentation, and failure to properly determine and monitor product yields—all resulting in adulterated drug products that violated section 501(a)(2) of the FDCA.
Argus analysis
# FDA Warning Letter Analysis: Pine Pharmaceuticals, LLC
**Company and Findings**
Pine Pharmaceuticals, LLC, a registered outsourcing facility in Tonawanda, New York, received a Warning Letter from the FDA's Center for Drug Evaluation and Research (CDER) on August 7, 2026, following an inspection conducted November 4–14, 2025. The FDA documented evidence of serious deficiencies in sterile drug manufacturing practices that posed patient risk. The agency determined that Pine Pharmaceuticals produced adulterated drug products in violation of the Federal Food, Drug, and Cosmetic Act (FDCA).
**Regulatory Citations and Implications**
The violations center on two statutory frameworks. First, section 501(a)(2)(A) of the FDCA addresses insanitary conditions that may render drugs injurious to health—investigators found operators failed to sanitize materials and hands before entering the ISO 5 critical area, and the environmental monitoring program did not adequately cover high-touch staging trays. Second, Current Good Manufacturing Practice (CGMP) violations under 21 CFR parts 210 and 211 included failures to investigate batch discrepancies (211.192), validate aseptic processes (211.113), ensure adequate personnel training (211.25), and calculate actual yield percentages (211.103). Notably, Pine Pharmaceuticals classified particulate matter and undefined "cosmetic" defects inconsistently with standard procedures, permitting contaminated batches to reach distribution.
**Timeline and Industry Watch Points**
Pine Pharmaceuticals submitted a response on December 8, 2025. The FDA noted inadequate supporting documentation and deficient corrective actions, particularly regarding tray sampling effectiveness and root-cause analysis of particulate contamination in distributed product. Peer compliance officers should monitor whether Pine Pharmaceuticals submits revised documentation addressing the agency's specific concerns about validation protocols, permanent procedure incorporation, and particulate investigation adequacy. Failure to demonstrate remediation may trigger regulatory action including product recalls, facility closure, or enforcement proceedings.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Compounding letters typically cite Section 503A (FDCA) for traditional compounders or Section 503B for outsourcing facilities, frequently combined with insanitary-conditions findings.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Pine Pharmaceuticals, LLC MARCS-CMS 728537 — August 07, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Recipient Name Alfonse J. Muto PharmD Recipient Title Owner Pine Pharmaceuticals, LLC 355 Riverwalk Parkway Tonawanda , NY 14150-5837 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER WL # 728537 August 7, 2026 Dear Dr. Muto: You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b] 1 on March 9, 2018, and most recently on November 19, 2025. From November 4, 2025, to November 14, 2025, FDA investigators inspected your facility, Pine Pharmaceuticals, LLC located at 355 Riverwalk Parkway, Tonawanda, NY 14150. During the inspection, the investigators collected evidence indicating serious deficiencies in your practices for producing drug products which put patients at risk. FDA issued a Form FDA 483 to your facility on November 14, 2025. We reviewed your December 8, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Based on this inspection, it appears you produced drugs that violate the FDCA. A. Compounded Drug Products under the FDCA Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met. An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211. B. Violations of the FDCA Adulterated Drug Products FDA investigators collected evidence indicating that drug products intended or expected to be sterile were prepared, packed, or held under insanitary…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Has Pine Pharmaceuticals, LLC had FDA enforcement actions before?
- Yes. Argus HQ has recorded 2 total FDA actions tied to Pine Pharmaceuticals, LLC: 1 warning letter, 0 recalls, and 0 approval records.
- What FDA violations was Pine Pharmaceuticals, LLC cited for?
- The FDA Warning Letter to Pine Pharmaceuticals, LLC (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Compounding Pharmacy/Adulterated Drug Products. Classification: Compounding (503A).
- When did FDA issue the warning letter to Pine Pharmaceuticals, LLC?
- FDA issued the letter (MARCS-CMS 728537) on 2026-08-07 and posted it publicly on fda.gov on 2026-10-06.
- Is the FDA warning letter to Pine Pharmaceuticals, LLC publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pine-pharmaceuticals-llc-728537-08072026.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Compounding Pharmacy/Adulterated Drug Products: FDA Warning Letter to Pine Pharmaceuticals, LLC, 2026-08-07. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-pine-pharmaceuticals-llc-2026-08-07-compounding
"Compounding Pharmacy/Adulterated Drug Products: FDA Warning Letter to Pine Pharmaceuticals, LLC, 2026-08-07." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-pine-pharmaceuticals-llc-2026-08-07-compounding.
Argus HQ Research. "Compounding Pharmacy/Adulterated Drug Products: FDA Warning Letter to Pine Pharmaceuticals, LLC, 2026-08-07." Digital Empire Holdings LLC. Accessed October 7, 2026. https://argushq.ai/fda/warning-letter/fda-wl-pine-pharmaceuticals-llc-2026-08-07-compounding.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_pine_pharmaceuticals_llc_2026_08_07_compounding_2026,
title = {Compounding Pharmacy/Adulterated Drug Products: FDA Warning Letter to Pine Pharmaceuticals, LLC, 2026-08-07},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-pine-pharmaceuticals-llc-2026-08-07-compounding},
note = {Accessed: October 7, 2026}
}